

Alder Biopharmaceuticals Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 15-Dec-2014

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)

ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 11

 Phase 2 Clinical..... 12

 Discovery..... 24

[Return to Table of Contents](#)

Alder Biopharmaceuticals Inc

COMPANY OVERVIEW

Company Name	Alder Biopharmaceuticals Inc
Parent Company Name	Alder Biopharmaceuticals Inc
Website	http://www.alderbio.com/
Country	US
Number of Drugs in Active Development	3
Number of Inactive Drugs	6
Number of Patents as Owner	18
Number of Patents as Third Party	0
Number of Deals	3
Key Indications	Rheumatoid arthritis, Anemia, Cachexia, Fatigue, Graft versus host disease, Migraine, Pain, Psoriatic arthritis, Crohns disease, Oral mucositis
Key Target-based Actions	Hepatocyte growth factor antagonist, NGF receptor antagonist, IL-6 antagonist, CGRP receptor antagonist, Proprotein convertase PC9 inhibitor, Interleukin-6 ligand inhibitor, Albumin agonist, C-reactive protein inhibitor, Albumin modulator, C-reactive protein modulator, CD126 antagonist, CGRP receptor agonist, Cytokine receptor agonist, Hepatocyte growth factor agonist, Interferon antagonist, Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor, Jak3 tyrosine kinase inhibitor, LDL receptor agonist, MAP kinase inhibitor, NGF receptor agonist, Proprotein convertase PC9 stimulator, STAT-3 inhibitor, Syk tyrosine kinase inhibitor, TNF alpha ligand, Triosephosphate dehydrogenase modulator, p38 MAP kinase inhibitor
Key Technologies	Biological therapeutic, Monoclonal antibody humanized, Parenteral formulation unspecified, Monoclonal antibody, Protein recombinant, Intravenous formulation, Subcutaneous formulation, Infusion, Antibody fragment, Antibody

COMPANY PROFILE

SUMMARY

Alder Biopharmaceuticals Inc, founded in January 2004, is focused on the identification, development and manufacture of antibody therapeutics for cancer, inflammatory, autoimmune and cardiovascular diseases.

LICENSING AGREEMENTS

In December 2005, Alder agreed to identify and manufacture Schering-Plough's antibody therapeutics. Using its yeast production system and high throughput antibody selection technology, Alder would work on up to ten Schering-Plough antibodies. Alder would receive milestone payments, research support and royalties. In June 2009, the agreement was expanded to include candidates with potential applications to central nervous system disorders. Alder would receive an upfront payment, milestones, royalties and committed funding for Alder personnel engaged in the project.

In November 2005, Alder agreed to use its yeast production system to produce research materials for one of Seattle Genetics' preclinical therapeutic antibodies.

FINANCIAL

In June 2014, the company was added to the Russell 3000 Index.

In May 2014, the company announced the pricing of its initial public offering of 8 million shares of its common stock at a price of \$10 per share. The shares had begun trading on the NASDAQ Global Market under the ticker symbol "ALDR". Alder had granted the underwriters a 30-day option to buy up to 1.2 million additional shares of common stock at the initial public offering price to cover over-allotments, if any. The offering was expected to close on May 13, 2014. Later that month, the offering was closed and the company raised net proceeds of \$80.1 million from the sale of an aggregate of 8,875,396 shares of its common stock, including 875,396 shares pursuant to the partial exercise of the underwriters' over-allotment option.

[Return to Table of Contents](#)



In April 2012, the company closed a \$38 million series D financing.

In January 2007, Alder raised \$40 million from a series C financing round.

In July 2006, Alder raised \$16 million in a series B financing round.


In August 2005, Alder raised \$11.1 million in a series A financing.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

Drugs by Indication Table

Indication	Active	Inactive	Total
Neurological disease	2	1	3
Neoplasm	0	2	2
Hematological disease	1	1	2
Inflammatory disease	1	1	2
Fatigue	1	0	1
Cardiovascular disease	0	1	1
Metabolic disorder	0	1	1
Nutritional disorder	1	0	1
Musculoskeletal disease	1	0	1
Immune disorder	1	0	1
Gastrointestinal disease	1	0	1
Mouth disease	1	0	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



[Return to Table of Contents](#)

Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	2
Discovery	1
No Development Reported	6

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Other Proprietary	1	0	0	0	1
Drug - Screening/Evaluation	1	0	0	0	1
Drug - Development/Commercialization License	1	0	0	0	1

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Neurological disease	1	4
Nutritional disorder	0	3
Immune disorder	0	3
Fatigue	0	2
Neoplasm	0	2
Musculoskeletal disease	0	2
Inflammatory disease	0	2
Respiratory disease	0	1
Hematological disease	0	1
Mouth disease	0	1

Trials by Phase

Phase	Ongoing	All
Phase 2	1	5
Phase 1	0	6

Phase Definitions

[Return to Table of Contents](#)

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	5	0	5
Endocrine disease	4	0	4
Gastrointestinal disease	7	0	7
Genitourinary disease	2	0	2
Growth disorder	1	0	1
Hematological disease	3	0	3
Degeneration	3	0	3
Immune disorder	6	0	6
Psychiatric disorder	1	0	1
Musculoskeletal disease	6	0	6
Neoplasm	10	0	10
Ocular disease	2	0	2
Metabolic disorder	3	0	3
Neurological disease	5	0	5
Nutritional disorder	5	0	5
Respiratory disease	3	0	3
Infectious disease	4	0	4
Injury	1	0	1
Inflammatory disease	7	0	7
Fatigue	3	0	3
Temperature disorder	1	0	1

[Return to Table of Contents](#)



Dermatological disease	1	0	1
------------------------	---	---	---

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

clazakizumab

clazakizumab SNAPSHOT

Drug Name	clazakizumab
Key Synonyms	clazakizumab
Originator Company	Alder Biopharmaceuticals Inc
Active Companies	Alder Biopharmaceuticals Inc
Inactive Companies	Bristol-Myers Squibb Co
Highest Status	Phase 2 Clinical
Active Indications	Anemia;Oral mucositis;Graft versus host disease;Cachexia;Fatigue;Crohns disease;Psoriatic arthritis;Rheumatoid arthritis
Target-based Actions	IL-6 antagonist
Other Actions	Anti-inflammatory
Technologies	Monoclonal antibody humanized;Subcutaneous formulation;Intravenous formulation;Infusion;Biological therapeutic;Protein recombinant
Last Change Date	03-Dec-2014

clazakizumab DEVELOPMENT PROFILE

SUMMARY

Alder Biopharmaceuticals is developing clazakizumab (ALD-518; BMS-945429), a neutralizing humanized monoclonal antibody against IL-6 produced in the company's Mab X-press yeast culture system, for the potential iv or sc treatment of cancer-related anemia, fatigue, cachexia, oral mucositis and graft versus host disease (GVHD). In November 2014, the company was seeking to outlicense the drug.

In September 2008, Alder initiated a phase II trial in cancer-related anemia, fatigue and cachexia ; in June 2010, positive results from the phase II study were presented, ; in July 2011, the drug was still listed as being in phase II development for these indications by Alder. In July 2011, a phase II oral mucositis trial was initiated. In March 2012, Alder initiated a phase I/II trial in GVHD patients. In June 2011, former licensee Bristol-Myers Squibb (BMS) initiated a phase IIb RA trial. In January 2012, BMS initiated a phase II psoriatic arthritis trial . In August 2012, a phase II Crohn's disease trial was initiated ; however, by June 2013, the trial had been terminated. In February 2014, the drug was listed as being in phase II development on BMS pipeline. However, in September 2014, BMS terminated its collaboration with Alder. At that time, Alder would continue development of drug for autoimmune/inflammatory diseases.

clazakizumab DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
---------	------------	---------	--------------------	------

[Return to Table of Contents](#)

Company	Indication	Country	Development Status	Date
Alder Biopharmaceuticals Inc	Anemia	US	Phase 2 Clinical	06-Jun-2010
Alder Biopharmaceuticals Inc	Cachexia	Australia	Phase 2 Clinical	30-Sep-2008
Alder Biopharmaceuticals Inc	Cachexia	Canada	Phase 2 Clinical	30-Sep-2008
Alder Biopharmaceuticals Inc	Cachexia	Eastern Europe	Phase 2 Clinical	30-Sep-2008
Alder Biopharmaceuticals Inc	Cachexia	Georgia	Phase 2 Clinical	30-Sep-2008
Alder Biopharmaceuticals Inc	Cachexia	India	Phase 2 Clinical	30-Sep-2008
Alder Biopharmaceuticals Inc	Cachexia	New Zealand	Phase 2 Clinical	30-Sep-2008
Alder Biopharmaceuticals Inc	Cachexia	Russian Federation	Phase 2 Clinical	30-Sep-2008
Alder Biopharmaceuticals Inc	Crohns disease	US	Phase 2 Clinical	02-Sep-2014
Alder Biopharmaceuticals Inc	Fatigue	Australia	Phase 2 Clinical	22-Jan-2009
Alder Biopharmaceuticals Inc	Fatigue	Canada	Phase 2 Clinical	30-Sep-2008
Alder Biopharmaceuticals Inc	Fatigue	Eastern Europe	Phase 2 Clinical	30-Sep-2008
Alder Biopharmaceuticals Inc	Fatigue	Georgia	Phase 2 Clinical	30-Sep-2008
Alder Biopharmaceuticals Inc	Fatigue	India	Phase 2 Clinical	30-Sep-2008
Alder Biopharmaceuticals Inc	Fatigue	New Zealand	Phase 2 Clinical	30-Sep-2008
Alder Biopharmaceuticals Inc	Fatigue	Russian Federation	Phase 2 Clinical	30-Sep-2008
Alder Biopharmaceuticals Inc	Graft versus host disease	US	Phase 2 Clinical	29-Mar-2012
Alder Biopharmaceuticals Inc	Oral mucositis	US	Phase 2 Clinical	25-Jul-2011
Alder Biopharmaceuticals Inc	Psoriatic arthritis	Argentina	Phase 2 Clinical	02-Sep-2014
Alder Biopharmaceuticals Inc	Psoriatic arthritis	Australia	Phase 2 Clinical	02-Sep-2014
Alder Biopharmaceuticals Inc	Psoriatic arthritis	Canada	Phase 2 Clinical	02-Sep-2014
Alder Biopharmaceuticals Inc	Psoriatic arthritis	EU	Phase 2 Clinical	02-Sep-2014

[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Alder Biopharmaceuticals Inc	Psoriatic arthritis	South Africa	Phase 2 Clinical	02-Sep-2014
Alder Biopharmaceuticals Inc	Psoriatic arthritis	US	Phase 2 Clinical	02-Sep-2014
Alder Biopharmaceuticals Inc	Rheumatoid arthritis	Canada	Phase 2 Clinical	31-Oct-2008
Alder Biopharmaceuticals Inc	Rheumatoid arthritis	Europe	Phase 2 Clinical	02-Sep-2014
Alder Biopharmaceuticals Inc	Rheumatoid arthritis	Far East	Phase 2 Clinical	02-Sep-2014
Alder Biopharmaceuticals Inc	Rheumatoid arthritis	Georgia	Phase 2 Clinical	31-Oct-2008
Alder Biopharmaceuticals Inc	Rheumatoid arthritis	India	Phase 2 Clinical	31-Oct-2008
Alder Biopharmaceuticals Inc	Rheumatoid arthritis	Italy	Phase 2 Clinical	02-Sep-2014
Alder Biopharmaceuticals Inc	Rheumatoid arthritis	Japan	Phase 2 Clinical	02-Sep-2014
Alder Biopharmaceuticals Inc	Rheumatoid arthritis	Russian Federation	Phase 2 Clinical	31-Oct-2008
Alder Biopharmaceuticals Inc	Rheumatoid arthritis	Serbia	Phase 2 Clinical	31-Oct-2008
Alder Biopharmaceuticals Inc	Rheumatoid arthritis	South Africa	Phase 2 Clinical	02-Sep-2014
Alder Biopharmaceuticals Inc	Rheumatoid arthritis	South America	Phase 2 Clinical	02-Sep-2014
Alder Biopharmaceuticals Inc	Rheumatoid arthritis	US	Phase 2 Clinical	31-Oct-2008
Bristol-Myers Squibb Co	Crohns disease	US	Discontinued	02-Sep-2014
Bristol-Myers Squibb Co	Psoriatic arthritis	Argentina	Discontinued	02-Sep-2014
Bristol-Myers Squibb Co	Psoriatic arthritis	Australia	Discontinued	02-Sep-2014
Bristol-Myers Squibb Co	Psoriatic arthritis	Canada	Discontinued	02-Sep-2014
Bristol-Myers Squibb Co	Psoriatic arthritis	EU	Discontinued	02-Sep-2014
Bristol-Myers Squibb Co	Psoriatic arthritis	South Africa	Discontinued	02-Sep-2014
Bristol-Myers Squibb Co	Psoriatic arthritis	US	Discontinued	02-Sep-2014
Bristol-Myers Squibb Co	Rheumatoid arthritis	Canada	Discontinued	02-Sep-2014
Bristol-Myers Squibb Co	Rheumatoid arthritis	Europe	Discontinued	02-Sep-2014
Bristol-Myers Squibb Co	Rheumatoid arthritis	Far East	Discontinued	02-Sep-2014

[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Bristol-Myers Squibb Co	Rheumatoid arthritis	Italy	Discontinued	02-Sep-2014
Bristol-Myers Squibb Co	Rheumatoid arthritis	Japan	Discontinued	02-Sep-2014
Bristol-Myers Squibb Co	Rheumatoid arthritis	South Africa	Discontinued	02-Sep-2014
Bristol-Myers Squibb Co	Rheumatoid arthritis	South America	Discontinued	02-Sep-2014
Bristol-Myers Squibb Co	Rheumatoid arthritis	US	Discontinued	02-Sep-2014

clazakizumab DRUG NAMES

Names	Type
anti-IL6 monoclonal antibody (rheumatoid arthritis/cancer), Alder Biopharmaceuticals/BMS	
clazakizumab	USAN, PINN
BMS-945429	Research Code
ALD-518	Research Code
anti-IL6 mAb (rheumatoid arthritis/cancer), Alder/Bristol-Myers Squibb	

clazakizumab SALES AND FORECASTS

COMMENTARY

CONSENSUS SALES INFORMATION

No Consensus forecast data for Alder Biopharmaceuticals are currently available.

REGIONAL DEVELOPMENT AND MARKETING RIGHTS

In November 2009, Bristol-Myers Squibb (BMS) entered into a worldwide, exclusive development and commercialization agreement for Alder Biopharmaceuticals' clazakizumab in all indications, including rheumatoid arthritis and other autoimmune diseases, but excluding oncology-associated conditions; at the time, this transaction was still pending approval [1056039]. By June 2011, the agreement had closed [1201269]. In September 2014, Alder BioPharmaceuticals regained worldwide rights to clazakizumab after BMS decided to end further development of the drug and terminated the agreement with Alder [1590051].

clazakizumab CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Rheumatoid arthritis											
0	0	0	0	2	3	0	1	0	0	2	4

[Return to Table of Contents](#)

Cachexia											
0	0	0	0	0	1	0	2	0	0	0	3
Fatigue											
0	0	0	0	0	1	0	1	0	0	0	2
Psoriatic arthritis											
0	0	0	0	1	1	0	0	0	0	1	1
Oral mucositis											
0	0	0	0	0	1	0	0	0	0	0	1
Metastatic non small cell lung cancer											
0	0	0	0	0	1	0	0	0	0	0	1
Cancer											
0	0	0	0	0	0	0	1	0	0	0	1
Graft versus host disease											
0	0	0	0	0	0	0	1	0	0	0	1
Crohns disease											
0	0	0	0	0	1	0	0	0	0	0	1
Anemia											
0	0	0	0	0	0	0	1	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	3	7	0	3	0	0	3	10

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical


Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

clazakizumab DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Alder Biopharmaceuticals Inc	1	0	0	0	1
Bristol-Myers Squibb Co	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Alder Biopharmaceuticals Inc	9	0	9
Bristol-Myers Squibb Co	4	1	4
Individual	1	0	1
UCB SA	0	1	1
Merck & Co Inc	1	0	1
GlaxoSmithKline plc	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Process	4
New use	4
General interest	3
Product	1

[Return to Table of Contents](#)

ALD-403

ALD-403 SNAPSHOT

Drug Name	ALD-403
Key Synonyms	
Originator Company	Alder Biopharmaceuticals Inc
Active Companies	Alder Biopharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Migraine
Target-based Actions	CGRP receptor antagonist
Other Actions	
Technologies	Monoclonal antibody humanized;Subcutaneous formulation;Intravenous formulation;Infusion;Biological therapeutic;Protein recombinant
Last Change Date	12-Dec-2014

ALD-403 DEVELOPMENT PROFILE

SUMMARY

Alder Biopharmaceuticals is developing ALD-403, a genetically engineered, humanized mAb that inhibits calcitonin gene-related peptide (CGRP), as a once-monthly sc and quarterly iv infusion, for the potential prevention of both episodic and chronic migraine . In October 2014, a phase IIb trial of the iv formulation in chronic migraine was initiated ; primary endpoint data were expected in the second half of 2015 . At that time, a phase IIb trial of the sc formulation for frequent episodic migraine was expected to begin in the first half of 2015 and a phase III trial of the iv formulation, which might combine both episodic and chronic migraine, was expected to be initiated in the second half of 2016 .

ALD-403 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Alder Biopharmaceuticals Inc	Migraine	US	Phase 2 Clinical	20-Oct-2014
Alder Biopharmaceuticals Inc	Migraine	Australia	Phase 1 Clinical	25-Apr-2012

[Return to Table of Contents](#)



ALD-403 DRUG NAMES

Names	Type
mAb (migraine), Alder	
ALD-403	Research Code
calcitonin gene-related peptide inhibitor (humanized mAb, migraine), Alder	
CGRP inhibitor (humanized mAb, migraine), Alder	

ALD-403 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Migraine											
0	0	0	0	1	2	0	2	0	0	1	4

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	1	2	0	3	0	0	1	5

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Alder Biopharmaceuticals Inc	5	0	5
University of Iowa	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Process	4
New use	1
Product	1
General interest	1

[Return to Table of Contents](#)

ALD-906

ALD-906 SNAPSHOT

Drug Name	ALD-906
Key Synonyms	
Originator Company	Alder Biopharmaceuticals Inc
Active Companies	Alder Biopharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Pain
Target-based Actions	NGF receptor antagonist
Other Actions	Analgesic
Technologies	Monoclonal antibody;Biological therapeutic;Parenteral formulation unspecified
Last Change Date	22-Nov-2012

ALD-906 DEVELOPMENT PROFILE

SUMMARY

Alder Biopharmaceuticals is investigating ALD-906, an anti-nerve growth factor (anti-NGF) mAb, for the potential treatment of pain. In February 2011, the program was listed as being in preclinical development ; in November 2012, this was still the case. In February 2011, the company was seeking to outlicense the program to strategic partners ; in November 2012, this was still the case.

ALD-906 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Alder Biopharmaceuticals Inc	Pain	US	Discovery	23-Feb-2011

ALD-906 DRUG NAMES

Names	Type
ALD-906	Research Code
anti-nerve growth factor monoclonal antibody (pain), Alder Biopharmaceuticals	
anti-NGF mAb (pain), Alder Biopharmaceuticals	


[Return to Table of Contents](#)



ALD-906 DEALS AND PATENTS

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Alder Biopharmaceuticals Inc	4	0	4

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Process	4
General interest	1

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)